Radiopharm Theranostics (NASDAQ:RADX) versus Bolt Biotherapeutics (NASDAQ:BOLT) Head-To-Head Survey

Bolt Biotherapeutics (NASDAQ:BOLT) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations.

Profitability

This table compares Bolt Biotherapeutics and Radiopharm Theranostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	N/A	-94.22%	-50.56%
Radiopharm Theranostics	N/A	N/A	N/A

Earnings & Valuation

This table compares Bolt Biotherapeutics and Radiopharm Theranostics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.69 million	1.35	-$63.12 million	($22.38)	-0.24
Radiopharm Theranostics	$2.35 million	24.42	-$24.83 million	N/A	N/A

Radiopharm Theranostics has lower revenue, but higher earnings than Bolt Biotherapeutics.

Institutional & Insider Ownership

86.7% of Bolt Biotherapeutics shares are held by institutional investors. 6.1% of Bolt Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Bolt Biotherapeutics and Radiopharm Theranostics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1	2	2	0	2.20
Radiopharm Theranostics	1	0	2	2	3.00

Bolt Biotherapeutics currently has a consensus price target of $34.00, suggesting a potential upside of 529.63%. Radiopharm Theranostics has a consensus price target of $15.33, suggesting a potential upside of 215.50%. Given Bolt Biotherapeutics’ higher probable upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Radiopharm Theranostics.

Summary

Radiopharm Theranostics beats Bolt Biotherapeutics on 6 of the 10 factors compared between the two stocks.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

About Radiopharm Theranostics

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.